REPORT SCOPE & OVERVIEW
Pancreatic Cancer Treatment Market size was valued at USD 2.8 billion in 2022 and is estimated to reach at USD 9.05 billion in 2030 and grow at a compound annual growth rate approx. CAGR of 15.8% predicted for the forecast period of 2023-2030.
High death rates and a poor prognosis are characteristics of pancreatic cancer. Since the cancer has frequently progressed to other organs by the time it is discovered, effective treatment might be difficult. Smoking, obesity, age, family history, and several genetic disorders are among the risk factors for the illness. Numerous strategies are used in the pancreatic cancer therapy landscape to enhance patient outcomes and survival rates. Surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and palliative care are some major categories for these therapeutic options. The main course of treatment for pancreatic cancer in its early stages is surgery. The entire pancreas may be removed in some circumstances, along with the tumour and its surrounding tissues. However, surgery is frequently not an option because of the disease's late stage upon diagnosis or the existence of metastases. High-energy radiation is used in radiation treatment to kill cancer cells and reduce tumour size. It can be applied as a palliative treatment, as a neoadjuvant before to surgery, as an adjuvant following surgery, or both to reduce symptoms and enhance quality of life.
Chemotherapy is a type of systemic medicine that employs chemicals to eradicate cancer cells all over the body. It can be given before or after radiation therapy or surgery, and these therapies are frequently combined with it. Gemcitabine is frequently used in pancreatic cancer chemotherapy regimens, as well as additional medications such FOLFIRINOX (folinic acid, fluorouracil, irinotecan, and oxaliplatin). A relatively recent development in the treatment of pancreatic cancer is targeted therapy. It entails the administration of medications that precisely target the genetic or molecular changes found in cancer cells, preventing the development and spread of such cells. Erlotinib and nab-paclitaxel are two instances of targeted treatments used to treat pancreatic cancer.
Growing Pancreatic Cancer Incidence, Technological Advances in Treatment Options Research and Development Activities are Growing.
An important market driver is the rising incidence of pancreatic cancer in the world. The ageing of the population, changes in lifestyle, and environmental factors all play a role in the disease's rising occurrence. For individuals with pancreatic cancer, new developments in surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy have increased their treatment choices. These developments have raised survival rates and enhanced treatment results. In the area of treating pancreatic cancer, research and development are given a lot of attention. Ongoing research aims to discover new therapeutic targets, create innovative medications, and investigate individualized therapy modalities. By elevating cutting-edge therapies, these initiatives advance the market.
Pancreatic Cancer Has an Aggressive Nature Negative effects of treatment and a lack of early detection methods.
The aggressiveness and propensity for metastasis of pancreatic cancer make it challenging to successfully treat. Successful treatment results are severely hampered by late-stage diagnosis and the lack of effective treatments for advanced illness. There are no trustworthy screening procedures accessible right now for the early diagnosis of pancreatic cancer. Because of this, a greater percentage of patients receive diagnoses at advanced stages, which restricts treatment options and lowers the likelihood of curative treatments. Surgery, chemotherapy, and radiation therapy are a few of the pancreatic cancer therapies that might have serious side effects that lower a patient's quality of life. Nausea, exhaustion, appetite loss, and gastrointestinal issues are possible side effects.
Approaches to Personalized Medicine Immunotherapy Developments.
The development of molecular profiling and genetic testing opens up the possibility of treating pancreatic cancer with personalized medication. The ability to target treatment plans and enhance results depends on the ability to detect particular genetic changes or biomarkers in individuals. A significant possibility is provided by the development of immunotherapies, such as immune checkpoint inhibitors, for the treatment of certain subgroups of pancreatic cancer patients. Treatment effectiveness may be improved by more investigation and clinical trials examining immunotherapy combinations and patient selection criteria.
High treatment costs Limited treatment options for advanced diseases Difficulties with reimbursement.
Treatment for pancreatic cancer, which may involve surgery, chemotherapy, targeted therapy, and immunotherapy, can be costly. Patients, healthcare systems, and reimbursement rules all face difficulties as a result of the high cost of these therapies. Options for people with advanced or metastatic pancreatic cancer are still limited despite improvements in therapy techniques. The market faces a significant difficulty in creating medicines that are successful for patients with late disease stages. It can be difficult and time-consuming to get regulatory clearance and payment for innovative medicines. The acceptance and accessibility of novel medicines can be impacted by regulatory restrictions, price negotiations, and reimbursement rules.
IMPACT OF RUSSIAN UKRAINE WAR
We constantly study the reports & news in light of the ongoing political and economic unpredictability caused by the Russia-Ukraine Conflict. Around the world, negative effects are anticipated, particularly in Eastern Europe, the European Union, Eastern & Central Asia, and the United States. This claim has significantly disrupted trade dynamics and had a negative impact on people's lives and means of subsistence. It is anticipated that the continued conflict and unpredictability in Eastern Europe would negatively affect Ukraine and have severe, long-lasting impacts on Russia. In light of the most recent information on the dispute and the responses from across the world, the paper explores the implications for demand-supply balances, pressure on pricing variations, influence on import/export and trade, and short-term advice to the United States market for pancreatic cancer therapeutics.
IMPACT OF ONGOING RECESSION
During the projection period of 2022-2030, the market's rise is anticipated to be aided by the growing geriatric population. The World Health Organisation (WHO) projects that by 2050, there will be approximately 2 billion geriatric people globally, up from an estimated 524 million in 2010. Geriatrics are more likely to need pancreatic cancer therapy because of their weakened immune systems, which is also predicted to accelerate market expansion and over the past two years, prices have increased significantly as a result of the high inflation rates in industrialised nations throughout the world. It is anticipated that the aggregate buying power would considerably affect emerging economies and is thought to be beneficial in many ways. The paper reveals how high inflation affects the long-term health of the global economy and offers information on the fiscal measures that may be taken to lessen its short-term effects on demand/supply, cash flow, and currency exchange. According to the United States Pancreatic Cancer Therapeutics Market research, there will be significant cost-push and demand-pull inflation in the next years.
KEY MARKET SEGMENTS
By Affected region
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of the Middle East & Africa
Rest of Latin American
The key players are Eli Lilly and Company, Celgene Corporation, F. Hoffmann-La Roche AG, Amgen Inc., Novartis AG, PharmaCyte Biotech Inc., Clovis Oncology, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Pfizer, Inc. and others.
Celgene Corporation-Company Financial Analysis
Pancreatic cancer dominated the global market in 2021. This is due to the fact that pancreatic cancer is more common in North American nations, with the USA having the highest worldwide cancer death rate. and as a result. With a large target population, North America had the highest revenue share in the pancreatic cancer treatment process. Additionally, there is a greater need for therapeutic alternatives due to the rising occurrence of pancreatic cancer.
The pancreatic cancer market is anticipated to grow the fastest in the Asia-Pacific region. As a result, it is anticipated that Asia Pacific would grow the quickest within the anticipated period. The Asia Pacific area will benefit from industry growth due to the presence of well-established clinics and critical care facilities as well as a sizable population suffering from pancreatic cancer. Additionally, since there are more incidences of pancreatic cancer in the Asia-Pacific region, diagnosis and treatment must follow the same guidelines as in Western countries.
Eli Lilly and Company;
Around 10 million children and adolescents with non-communicable illnesses will benefit from improved healthcare facilities according to a partnership announced by Eli Lilly & Company and UNICEF in February 2022.
Regarding pancreatic cancer, the FDA granted Novartis' monoclonal antibody NIS793 the Orphan Drug Designation (ODD) in July 2021.
|Market Size in 2022
|US$ 2.8 Bn
|Market Size by 2030
|US$ 9.05 Bn
|CAGR of 15.8% From 2023 to 2030
|Report Scope & Coverage
|Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
|• By Affected region (Exocrine, Endocrine)
• By Type (Chemotherapy, Targeted Therapy, Others)
|North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Eli Lilly and Company, Celgene Corporation, F. Hoffmann-La Roche AG, Amgen Inc., Novartis AG, PharmaCyte Biotech Inc., Clovis Oncology, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Pfizer, Inc. and others.
|• Growing Pancreatic Cancer Incidence, Technological Advances in Treatment Options Research and Development Activities are Growing.
|• Approaches to Personalized Medicine Immunotherapy Developments.
Ans: The CAGR Growth rate of Pancreatic Cancer Treatment Market is approx. CAGR 15.8% for the forecast period of 2023-2030.
Ans: The projected market size of Pancreatic Cancer Treatment Market at USD 2.8 billion in 2022 and is poised to reach at 9.05 billion in 2030.
Ans: The Key Players are Eli Lilly and Company, Celgene Corporation, F. Hoffmann-La Roche AG, Amgen Inc., Novartis AG, PharmaCyte Biotech Inc., Clovis Oncology, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Pfizer, Inc. and others.
Ans: The market will be driven by the condition's rising prevalence and the release of new drugs.
Ans: The largest market share is anticipated to be held by North America.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of the Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
126.96.36.199 United Kingdom
188.8.131.52 South Korea
184.108.40.206 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Pancreatic Cancer Treatment Market, By Affected Region
9. Pancreatic Cancer Treatment Market, By Types
9.2 Targeted Therapy
10. Regional Analysis
10.2 North America
10.2.1 North America Pancreatic Cancer Treatment Market, by country
10.2.2North America Pancreatic Cancer Treatment Market by Affected Region
10.2.3 North America Pancreatic Cancer Treatment Market by Type
10.2.4.1 USA Pancreatic Cancer Treatment Market by Affected Region
10.2.4.2 USA Pancreatic Cancer Treatment Market by Type
10.2.7.1 Canada Pancreatic Cancer Treatment Market by Affected Region
10.2.7.2 Canada Pancreatic Cancer Treatment Market by Type
10.2.8.1 Mexico Pancreatic Cancer Treatment Market by Affected Region
10.2.8.2 Mexico Pancreatic Cancer Treatment Market by Type
10.3.1 Europe Pancreatic Cancer Treatment Market by country
220.127.116.11 Europe Pancreatic Cancer Treatment Market by Affected Region
10.3.3 Europe Pancreatic Cancer Treatment Market by Type
10.3.6.1 Germany Pancreatic Cancer Treatment Market by Affected Region
10.3.6.2 Germany Pancreatic Cancer Treatment Market by Type
10.3.7.1 UK Pancreatic Cancer Treatment Market by Affected Region
10.3.7.2 UK Pancreatic Cancer Treatment Market by Type
10.3.8.1 France Pancreatic Cancer Treatment Market by Affected Region
10.3.8.2 France Pancreatic Cancer Treatment Market by Type
10.3.9.1 Italy Pancreatic Cancer Treatment Market by Affected Region
10.3.9.2 Italy Pancreatic Cancer Treatment Market by Type
10.3.10.1 Spain Pancreatic Cancer Treatment Market by Affected Region
10.3.10.2 Spain Pancreatic Cancer Treatment Market by Type
10.3.11 The Netherlands
10.3.11.1 Netherlands Pancreatic Cancer Treatment Market by Affected Region
10.3.11.2 Netherlands Pancreatic Cancer Treatment Market by Type
10.3.12 Rest of Europe
10.3.12.1 Rest of Europe Pancreatic Cancer Treatment Market by Affected Region
10.3.12.2 Rest of Europe Pancreatic Cancer Treatment Market by Type
10.4.1 Asia Pacific Pancreatic Cancer Treatment Market by country
10.4.2 Asia Pacific Pancreatic Cancer Treatment Market by Affected Region
10.4.3 Asia Pacific Pancreatic Cancer Treatment Market by Type
10.4.6.1 Japan Pancreatic Cancer Treatment Market by Affected Region
10.4.6.2 Japan Pancreatic Cancer Treatment Market by Type
10.4.7 South Korea
10.4.7.1 South Korea Pancreatic Cancer Treatment Market by Affected Region
10.4.7.2 South Korea Pancreatic Cancer Treatment Market by Type
10.4.8.1 China Pancreatic Cancer Treatment Market by Affected Region
10.4.8.2 China Pancreatic Cancer Treatment Market by Type
10.4.9.1 India Pancreatic Cancer Treatment Market by Affected Region
10.4.9.2 India Pancreatic Cancer Treatment Market by Type
10.4.10.1 Australia Pancreatic Cancer Treatment Market by Affected Region
10.4.10.2 Australia Pancreatic Cancer Treatment Market by Type
10.4.11 Rest of Asia-Pacific
10.4.11.1 APAC Pancreatic Cancer Treatment Market by Affected Region
10.4.11.2 APAC Pancreatic Cancer Treatment Market by Type
10.5 The Middle East & Africa
10.5.1 The Middle East & Africa Pancreatic Cancer Treatment Market by country
10.5.2 The Middle East & Africa Pancreatic Cancer Treatment Market by Affected Region
10.5.3 The Middle East & Africa Pancreatic Cancer Treatment Market by Type
10.5.6.1 Israel Pancreatic Cancer Treatment Market by Affected Region
10.5.6.2 Israel Pancreatic Cancer Treatment Market by Type
10.5.7.1 UAE Pancreatic Cancer Treatment Market by Affected Region
10.5.7.2 UAE Pancreatic Cancer Treatment Market by Type
10.5.8 South Africa
10.5.8.1 South Africa Pancreatic Cancer Treatment Market by Affected Region
10.5.8.2 South Africa Pancreatic Cancer Treatment Market by Type
10.5.9 Rest of Middle East & Africa
10.5.9.1 Rest of Middle East & Asia Pancreatic Cancer Treatment Market by Affected Region
10.5.9.2 Rest of Middle East & Asia Pancreatic Cancer Treatment Market by Type
10.6 Latin America
10.6.1 Latin America Pancreatic Cancer Treatment Market by country
10.6.2 Latin America Pancreatic Cancer Treatment Market by Affected Region
10.6.3 Latin America Pancreatic Cancer Treatment Market by Type
10.6.6.1 Brazil Pancreatic Cancer Treatment Market by Affected Region
10.6.6.2 Brazil Africa Pancreatic Cancer Treatment Market by Type
10.6.7.1 Argentina Pancreatic Cancer Treatment Market by Affected Region
10.6.7.2 Argentina Pancreatic Cancer Treatment Market by Type
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Pancreatic Cancer Treatment Market by Affected Region
10.6.8.2 Rest of Latin America Pancreatic Cancer Treatment Market by Type
12 Company profile
12.1 Eli Lilly and Company,
12.1.1 Market Overview
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Celgene Corporation
12.2.1 Market Overview
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 F. Hoffmann-La Roche AG
12.3.1 Market Overview
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Amgen Inc.
12.4.1 Market Overview
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Novartis AG.
12.5.1 Market Overview
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 PharmaCyte Biotech Inc.
12.6.1 Market Overview
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Clovis Oncology.
12.7.1 Market Overview
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Teva Pharmaceutical Industries Ltd.
12.8.1 Market Overview
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Merck & Co., Inc.
12.9.1 Market Overview
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Pfizer, Inc.
12.10.1 Market Overview
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments
14. Use Case and Best Practices
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Healthcare Claims Management Market Size was valued at USD 13.52 billion in 2022, and is expected to reach USD 21.39 billion by 2030, and grow at a CAGR of 5.9% over the forecast period 2023-2030.
The 3D Printed Brain Model Market Size was valued at USD 32.82 million in 2022 and is expected to reach USD 109.11 million by 2030, and grow at a CAGR of 16.2% over the forecast period 2023-2030.
The ECG Equipment and Management System market is anticipated to arrive at USD 9.77 billion by 2030. From 2023 to 2030, the market is assessed to develop at a CAGR of 6.38%.
The Scoliosis Management Market size was USD 1880.20 Million in 2022 and is expected to Reach USD 2653.43 Million by 2030 and grow at a CAGR of 4.4% over the forecast period of 2023-2030.
The Clinical Trial Imaging Market Size was valued at USD 925.01 million in 2022, and is expected to reach USD 1818 million by 2030 and grow at a CAGR of 8.8% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone